Not available
NCT03089905
Not available
There is considerable evidence that most general anaesthetics modulate brain development in animal studies. The impact is greater with longer durations of exposure and in younger animals. There is great controversy over whether or not these animal data are relevant to human clinical scenarios. The changes seen in preclinical studies are greatest with GABA agonists and NMDA antagonists such as volatile anaesthetics (eg sevoflurane), propofol, midazolam, ketamine, and nitrous oxide. There is less .... Read more
Inclusion Criteria: * Younger than 2 years (chronological age) * Scheduled for anaesthesia that is expected to last at least 2 hours (and/or total operating room time is scheduled to be at least 2.5 hours) * Has a legally acceptable representative capable of understanding the informed consent document and providing consent on the participant's behalf. Exclusion Criteria: * Known neurologic, chromosomal or congenital anomaly which is likely to be associated with poor neurobehavioural outcome * Ex .... Read more
No
Sample Size Not Available
Min. age N/A
Max. age 2 Years
Sex All
Condition category Not Available
Condition code Anesthesia , Neurotoxicity , Child Development
Intervention code Treatment: Drugs - Sevoflurane , Treatment: Drugs - Remifentanil , Treatment: Drugs - Dexmedetomidine
Sevoflurane/dexmedetomidine/remifentanil Experimental Dexmedetomidine: loading dose of 1mcg/kg over 10 minutes followed by an infusion of at 1 mcg/kg/hr. Remifentanil: loading dose 1 mcg/kg over 2 minutes followed by an infusion starting at 0.1 mcg/kg/min or greater. Sevoflurane: end tidal concentration of 0.6 -0.8% or less. Sevoflurane Active comparator End tidal concentration of 2.5-3.0% or greater. Treatment: Drugs: Sevoflurane Experimental arm: end tidal concentration of 0.6 -0.8% or less. A .... Read more
Control group Not available
Comparison not available.
Not Available
Yes
STUDY_PROTOCOL,SAP,ICF,CSR,ANALYTIC_CODE
6 months after publication of primary outcome
Prior to releasing any data the following are required: a data access agreement must be signed between relevant parties, the TREX Trial Steering Committee must see and approve the analysis plan describing how the data will be analysed, there must be an agreement around appropriate acknowledgement and any additional costs involved must be covered. Data will only be shared with a recognised research institution which has approved the proposed analysis plan.
To assist secondary data users in understanding the real-world impact of health and medical research data sharing, the Australian Research Data Commons (ARDC) has created an online guide that outlines a theoretical framework for four key data reuse scenarios. This practical guide was extracted from research papers, and consultation with stakeholders and the research community.
With Health Data Australia, researchers can explore descriptions of data from our publishing partners, identify relevant datasets, and request access. These requests will then be forwarded to the data owner for review.
To start requesting data, simply login with your AAF account.